OncoCyte Corp expected to post a loss of 67 cents a share - Earnings Preview

Insight Molecular Diagnostics

13/05/2024 21:27

* OncoCyte Corp  OCX.OQ   OCX.O  is expected to show a rise
in
quarterly revenue when it reports  results on May 15 for the
period ending March 31 2024
    * The Irvine California-based  company is expected to report
a
17.8% increase in revenue to $350 thousand from $297 thousand a
year ago, according to the mean estimate from 3 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for OncoCyte Corp is for a
loss
of 67 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for OncoCyte
Corp is
$4.13​, above​ its last closing price of $2.89. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023              -1.14      -2.12     Missed  -86.5
 Sep. 30 2023  -1.00       -1.01      -0.81     Beat    19.6
 Jun. 30 2023  -0.68       -1.30      -1.07     Beat    17.7​
 Mar. 31 2023  -1.31       -1.84      0.40      Beat    121.7
 ​​Dec.                    -1.88      -8.00     Missed  -324.6
 31 2022                                                
 Sep. 30 2022  -2.28       -2.26      -1.60     Beat    29.1​
 Jun. 30 2022  -2.32       -2.39      -1.40     Beat    41.3
 Jan. 1 0001   -2.34       -2.40      -2.20     Beat    8.3
 This summary was machine generated May 13 at 20:27 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)